Human genetic evidence supports fibroblast growth factor 21 as a novel therapeutic target for gout

Journal Article Accepted manuscript Human genetic evidence supports Fibroblast Growth Factor 21 (FGF21) as a novel therapeutic target for gout Get access Sizheng Steven Zhao, Sizheng Steven Zhao Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK Correspondence to: Sizheng S Zhao. Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Oxford Road, Manchester, M13 9LJ, UK. Email: Sizheng.zhao@manchester.ac.uk Search for other works by this author on: Oxford Academic PubMed Google Scholar Daniel J Cuthbertson, Daniel J Cuthbertson Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UKLiverpool University Hospitals NHS Foundation Trust, Liverpool, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Uazman Alam Uazman Alam Liverpool University Hospitals NHS Foundation Trust, Liverpool, UKDepartment of Cardiovascular and Metabolic Medicine, Liverpool Centre for Cardiovascular Science and the Pain Research Institute, University of Liverpool, Liverpool, UKCentre for Biomechanics and Rehabilitation Technologies, Staffordshire University Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, keae210, https://doi.org/10.1093/rheumatology/keae210 Published: 29 March 2024 Article history Received: 19 March 2024 Accepted: 25 March 2024 Published: 29 March 2024